COO logo

The Cooper Companies, Inc. (COO) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

The Cooper Companies, Inc. (COO), Healthcare sektöründe faaliyet gösteriyor, son olarak 72.05$'dan işlem görüyor ve $14.06B piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 53/100 puan alıyor.

Son analiz: 9 Şub 2026
53/100 AI Puanı PD $14.06B Hacim 1.72M

The Cooper Companies, Inc. (COO) Sağlık ve Boru Hattı Genel Bakışı

CEOAlbert G. White
Çalışanlar16000
MerkezSan Ramon, CA, US
Halka Arz Yılı1983
SektörHealthcare

The Cooper Companies (COO) offers a notable research candidate driven by its strong market position in vision care and women's health, boasting a 9.2% profit margin and a diverse product portfolio poised to capitalize on growing global healthcare demands and innovative solutions.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 9 Şub 2026

Yatırım Tezi

The Cooper Companies presents a notable research candidate due to its established market positions in the growing vision care and women's health sectors. With a current market capitalization of $16.32 billion and a profit margin of 9.2%, COO demonstrates financial stability. Growth catalysts include the increasing prevalence of vision disorders and the rising demand for advanced fertility solutions. The company's focus on innovation and strategic acquisitions should drive revenue growth. The current P/E ratio of 43.38 suggests a premium valuation, but this is justified by the company's consistent performance and future growth prospects. Investors may want to evaluate COO for long-term capital appreciation.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market Cap of $16.32B reflecting substantial investor confidence and market valuation.
  • P/E Ratio of 43.38 indicating investor expectations of future earnings growth.
  • Profit Margin of 9.2% demonstrating effective cost management and profitability.
  • Gross Margin of 64.3% showcasing the company's ability to maintain high revenue relative to the cost of goods sold.
  • Beta of 1.03 indicating the stock's volatility is similar to the overall market.

Rakipler & Benzerleri

Güçlü Yönler

  • Strong market position in both vision care and women's health.
  • Diverse product portfolio catering to various customer needs.
  • Global distribution network providing access to a wide range of markets.
  • Consistent financial performance with healthy profit margins.

Zayıflıklar

  • High P/E ratio indicating a premium valuation.
  • Dependence on specific product lines for revenue generation.
  • Exposure to regulatory risks in the medical device industry.
  • Potential impact from currency fluctuations.

Katalizörler

  • Upcoming: Launch of new innovative contact lens products targeting myopia control.
  • Ongoing: Expansion of CooperSurgical's fertility solutions and services in key markets.
  • Ongoing: Strategic acquisitions to expand product portfolio and market reach.
  • Ongoing: Increasing demand for vision correction and women's health products globally.

Riskler

  • Potential: Product recalls or safety concerns affecting brand reputation.
  • Potential: Changes in healthcare regulations and reimbursement policies.
  • Ongoing: Increasing competition from established and emerging players.
  • Ongoing: Economic downturns impacting consumer spending on healthcare products.
  • Ongoing: Currency fluctuations affecting international revenue.

Büyüme Fırsatları

  • Expanding the CooperVision segment in emerging markets: The increasing prevalence of vision problems in developing countries presents a significant growth opportunity. By expanding its distribution network and tailoring products to meet the specific needs of these markets, CooperVision can capture a larger share of the global contact lens market. This expansion could contribute significantly to revenue growth over the next 3-5 years, potentially increasing sales by 15-20%.
  • Developing innovative contact lens technologies: Investing in research and development to create advanced contact lenses that address specific needs, such as myopia control or digital eye strain, can attract new customers and retain existing ones. The market for specialized contact lenses is growing rapidly, with an estimated market size of $2 billion. Successfully launching these innovative products could boost CooperVision's revenue by 10-15% within 2-3 years.
  • Growing the CooperSurgical segment through strategic acquisitions: Acquiring companies with complementary products or technologies in the women's health space can expand CooperSurgical's product portfolio and market reach. The women's health market is estimated to be worth $40 billion, and strategic acquisitions can provide access to new customer segments and distribution channels. This strategy could increase CooperSurgical's revenue by 20-25% over the next 3-4 years.
  • Enhancing fertility solutions and services: The increasing demand for fertility treatments presents a significant growth opportunity for CooperSurgical. By expanding its range of fertility products and services, including consumables, equipment, and genetic testing, the company can cater to a larger segment of the market. The global fertility market is projected to reach $36 billion by 2026, offering substantial growth potential for CooperSurgical.
  • Leveraging digital health solutions: Integrating digital health technologies into Cooper Companies' product offerings can enhance patient engagement and improve outcomes. Developing mobile apps or online platforms that provide personalized vision care or women's health advice can attract new customers and strengthen brand loyalty. The digital health market is experiencing rapid growth, with an estimated market size of $280 billion, presenting a significant opportunity for Cooper Companies to innovate and expand its reach.

Fırsatlar

  • Expanding into emerging markets with growing healthcare needs.
  • Developing innovative products and technologies to address unmet needs.
  • Acquiring companies with complementary products or technologies.
  • Leveraging digital health solutions to enhance patient engagement.

Tehditler

  • Increasing competition from established and emerging players.
  • Changes in healthcare regulations and reimbursement policies.
  • Economic downturns impacting consumer spending on healthcare products.
  • Product recalls or safety concerns affecting brand reputation.

Rekabet Avantajları

  • Strong brand reputation in the vision care and women's health markets.
  • Extensive product portfolio catering to diverse customer needs.
  • Global distribution network providing access to a wide range of markets.
  • Proprietary technologies and intellectual property protecting product innovation.

COO Hakkında

Founded in 1958 and headquartered in San Ramon, California, The Cooper Companies, Inc. has evolved into a prominent global medical device company. The company operates through two primary segments: CooperVision and CooperSurgical. CooperVision focuses on manufacturing and marketing a wide array of contact lenses, including spherical, toric, and multifocal lenses, addressing various vision correction needs such as nearsightedness, farsightedness, astigmatism, and presbyopia. These lenses are distributed across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. CooperSurgical is dedicated to women's health, offering medical devices, fertility solutions, genomics, diagnostics, and contraception to healthcare professionals and patients worldwide. Their product range encompasses surgical and office products like PARAGARD, uterine manipulators, retractors, closure products, and fertility products and services, including consumables, equipment, embryo options, and preimplantation genetic testing. With a workforce of 16,000 employees, Cooper Companies continues to expand its global footprint and innovate within the medical device industry, holding a significant position in both vision care and women's health markets.

Ne Yaparlar

  • Develop, manufacture, and market a wide range of contact lenses.
  • Offer spherical lenses for correcting nearsightedness and farsightedness.
  • Provide toric and multifocal lenses for astigmatism and presbyopia.
  • Manufacture medical devices for women's health.
  • Offer fertility products and services, including consumables and equipment.
  • Provide surgical and office products for healthcare professionals.
  • Offer genomics, diagnostics, and contraception solutions.

İş Modeli

  • Develop and manufacture contact lenses and women's health products.
  • Distribute products through healthcare professionals and retailers.
  • Generate revenue through product sales and service offerings.
  • Invest in research and development to innovate and expand product lines.

Sektör Bağlamı

The Cooper Companies operates within the medical instruments and supplies industry, a sector experiencing steady growth driven by an aging global population and increasing healthcare spending. The market is competitive, with key players like DOCS and FMS vying for market share. The industry is also influenced by technological advancements, such as new materials for contact lenses and minimally invasive surgical techniques. Cooper Companies is well-positioned to capitalize on these trends through its focus on innovation and strategic acquisitions, maintaining a competitive edge in both the vision care and women's health segments.

Kilit Müşteriler

  • Contact lens wearers with vision correction needs.
  • Healthcare professionals in the vision care and women's health fields.
  • Hospitals and clinics offering fertility treatments.
  • Patients seeking fertility solutions and women's health services.
AI Güveni: 73% Güncellendi: 9 Şub 2026

Finansallar

Grafik & Bilgi

The Cooper Companies, Inc. (COO) hisse senedi fiyatı: $72.05 (+0.00, +0.00%)

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

COO için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

COO için Wall Street fiyat hedefi analizi.

MoonshotScore

53/100

Bu puan ne anlama geliyor?

MoonshotScore, COO'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

The Cooper Companies, Inc. Hissesi: Cevaplanan Temel Sorular

COO için değerlendirilmesi gereken temel faktörler nelerdir?

The Cooper Companies, Inc. (COO) şu anda yapay zeka skoru 53/100, orta puanı gösteriyor. Temel güçlü yan: Strong market position in both vision care and women's health.. İzlenmesi gereken birincil risk: Potential: Product recalls or safety concerns affecting brand reputation.. Bu bir finansal tavsiye değildir.

COO MoonshotScore'u nedir?

COO şu anda MoonshotScore'da 53/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

COO verileri ne sıklıkla güncellenir?

COO fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler COO hakkında ne diyor?

COO için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

COO'a yatırım yapmanın riskleri nelerdir?

COO için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Product recalls or safety concerns affecting brand reputation.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

COO'ın P/E oranı nedir?

COO için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için COO'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

COO aşırı değerli mi, yoksa düşük değerli mi?

The Cooper Companies, Inc. (COO)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

COO'ın temettü verimi nedir?

The Cooper Companies, Inc. (COO) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Fiyat itibarıyla Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data is based on the most recent available information.
  • Future performance is subject to market conditions and company-specific factors.
Veri Kaynakları

Popüler Hisseler